LGALS9 and neoplasm: This may be due to the intimate interaction between MSCs and tumor tissues, and thus the targeted co-delivery of oxaliplatin (OXA) which can induce immunogenic cell death (ICD) and galectin-9 siRNA which is responsible for tumor immunosuppression reversal induces a significant synergistic effect for pancreatic ductal adenocarcinoma treatment (Zhou et al., 2021).